Genmab, Janssen discontinue Darzalex combo trials

Genmab A/S (CSE:GEN; Pink:GMXAY) said partner Janssen Biotech Inc. will discontinue two studies of Darzalex daratumumab in combination with different immune checkpoint inhibitors.

The studies include the open-label, international Phase Ib/II CALLISTO/LUC2001 trial, which is evaluating Darzalex plus PD-L1 inhibitor Tecentriq atezolizumab to treat non-small cell lung cancer (NSCLC); and the open-label, international Phase I MMY2036 trial of Darzalex plus JNJ-63723283, an anti-PD-1 mAb, to treat multiple myeloma...